Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Medigen In-licenses Asian Rights for Cancer Drug

publication date: Mar 19, 2008

Medigen Biotechnology Corp., a biotech company based in Taiwan, has in-licensed key rights for a cancer drug from Oncolys BioPharma, Inc. of Japan. Medigen will pay up to $198.9 million, including milestones, for the right to develop OBP-301 for liver cancer or an alternative indication. Plus, upon completing Phase II studies, Medigen will also have the option to acquire the Asian rights, including China and Japan, to the drug for all indications. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital